Marylaure Gavard

Marylaure Gavard

Auto-generated profile, based on publicly available information

Marylaure Gavard

Cellule de vigilance des essais cliniques-délégation à la recherche clinique et à l'innovation - CHU de Grenoble-Alpes, 38043 Grenoble, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Radiotherapy and Oncology
Verified
Journal Article
Open access
CVCamille Verry
Camille Verry
SDSandrine Dufort
Sandrine Dufort
JVJulie Villa
Julie Villa
MGMarylaure Gavard
Marylaure Gavard
CICarole Iriart
Carole Iriart
JBJacques Balosso
Jacques Balosso
Brain metastasis impacts greatly on patients' quality of life and survival. The phase I NANO-RAD trial assessed the safety and maximum tolerated dose of systemic administration of a novel gadolinium-based nanoparticle, AGuIX, in combination with whole brain radiotherapy in patients with multiple brain metastases not suitable for stereotactic radiotherapy. Patients with measurable brain metastases received escalating doses of AGuIX nanoparticles (15, 30, 50, 75, or 100 mg/kg intravenously) on the day of initiation of WBRT (30 Gy in 10 fractions) in 5 cohorts of 3 patients each. Toxicity was assessed using NCI Common Terminology Criteria for Adverse Events v4.03. Fifteen patients with 354 metastases were included. No dose-limiting toxic effects were observed up to AGuIX 100 mg/kg. Plasma elimination half-life of AGuIX was similar for all groups (mean 1.3 h; range 0.8-3 h). Efficient targeting of metastases (T1 MRI enhancement, tumor selectivity) and persistence of AGuIX contrast enhancement were observed in metastases from patients with primary melanoma, lung, breast, and colon cancers. The concentration of AGuIX in metastases after administration was proportional to the injected dose. Thirteen of 14 evaluable patients had a clinical benefit, with either stabilization or reduction of tumor volume. MRI analysis showed significant correlation between contrast enhancement and tumor response, thus supporting a radiosensitizing effect. Combining AGuIX with radiotherapy for patients with brain metastases is safe and feasible. AGuIX specifically targets brain metastases and is retained within tumors for up to 1 week; ongoing phase II studies will more definitively assess efficacy.

1 November 2021 in Therapies
Verified
Journal Article
Closed access
NPNadine Petitpain
Nadine Petitpain
POPascale Olivier
Pascale Olivier
SCSabrina Crépin
Sabrina Crépin
ELEmanuela Leone
Emanuela Leone
TOThavarak Ouk
Thavarak Ouk
MGMarylaure Gavard
Marylaure Gavard